Comparing Neurotoxins

Despite slight differences in behavior, botulinum toxin brand preference often relies on past experience.
MedEsthetics Nov/Dec 2019

When it comes to smoothing wrinkles and minimizing signs of aging, injectable neurotoxins remain one of the most popular options. According to the American Society of Plastic Surgeons, 7.44 million botulinum toxin type A procedures were performed in 2018, which is up 3 percent from the previous year.

Galderma Celebrates Charitable Partnerships for Month of June

Patients undergoing treatment with Dysport during the month of June are helping to support three impactful charities thanks to a partnership between Galderma, Dress for Success, PAWS and The National Coalition Against Domestic Violence (NCADV).

Until June 30, for every Dysport aesthetic treatment administered in select markets nationwide from a licensed healthcare provider and recorded in the ASPIRE Galderma Rewards loyalty program, $25-$100 will be donated to Dress for Success, PAWS or the NCADV as follows:

Modulating Expression

Physicians share their techniques for obtaining better longevity and more natural-looking results with botulinum toxins.
Improving longevity and outcomes with neurotoxins

What started as a simple injection to lessen crow’s feet has blossomed into a multibillion dollar market and given rise to today’s medical aesthetics industry. With nearly 30 years of experience and a growing variety of botulinum toxins entering the market, the current focus in neuromodulation is on extending the longevity of results and delivering natural-looking outcomes.

Comparing Three Botulinum Toxins

Comparing Three Botulinum Toxins

A study in Plastic and Reconstructive Surgery (May 2016) used digital image correlation to compare dynamic strain reduction between three U.S. Food and Drug Administration (FDA)-approved formulations of botulinum toxin: onabotulinumtoxinA (Botox, Allergan), abobotulinumtoxinA (Dysport, Galderma) and incobotulinumtoxinA (Xeomin, Merz).

AbobotulinumtoxinA may offer faster onset of action and longer duration of results

A split-face study comparing the onset of action, change in degree of wrinkles, patient satisfaction, duration of effect and adverse effects of OnabotulinumtoxinA (ONA; Botox, Allergan, and AbobotulinumtoxinA (ABO; Dysport, Valeant Pharmaceuticals) has revealed subtle differences between the two popular injectables. Ramtin Kassir, MD, et al, treated 85 patients aged 18-75 with moderate to severe wrinkles in either the glabellar or crow’s feet area, or both. Patients who had conditions that would interefere with the assessment of wrinkles were excluded.